Stance Capital LLC Sells 38,814 Shares of Boston Scientific Corporation $BSX

Stance Capital LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 92.6% in the second quarter, HoldingsChannel reports. The firm owned 3,083 shares of the medical equipment provider’s stock after selling 38,814 shares during the quarter. Stance Capital LLC’s holdings in Boston Scientific were worth $331,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Riverwater Partners LLC increased its stake in shares of Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management increased its position in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 99 shares during the period. IVC Wealth Advisors LLC increased its position in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the period. Rise Advisors LLC raised its holdings in Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC lifted its position in shares of Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 0.9%

BSX stock opened at $92.58 on Monday. The business has a 50 day moving average of $98.85 and a 200 day moving average of $101.59. The firm has a market cap of $137.24 billion, a PE ratio of 49.51, a price-to-earnings-growth ratio of 1.86 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the company posted $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BSX shares. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday. UBS Group increased their target price on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Needham & Company LLC restated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Friday, October 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $124.43.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.